Improving the Efficacy of Anti-Nicotine Immunotherapy (PETNic002)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Center for Nicotine & Smoking Cessation Research
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-55 years old
- Smoked an average of at least 10 cigarettes per day for the past year
- Have an expired air Carbon Monoxide (CO) reading of at least 15 ppm
- Express a desire to quit smoking in the next three to four months.
- Potential subjects must agree to use acceptable contraception during their participation in this study.
- Potential subjects must agree to avoid the following during their participation in this study:
- participation in any other nicotine-related modification strategy outside of this protocol
use of tobacco products other than cigarettes, including pipe tobacco, cigars, snuff, and chewing tobacco
- use of experimental (investigational) drugs or devices;
- use of illegal drugs;
- use of psychiatric medications;
- use of opiate medications;
- use of systemic steroids or other immunosuppressive agents.
Exclusion Criteria:
- Hypertension (systolic >140 mm Hg, diastolic >100 mm Hg, coupled with a history of hypertension); subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100.
- Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg).
- Participants with a history of hypertension may, however, be allowed to participate in the study if the study physician or physician assistant determines that the condition is stable, controlled by medication, and in no way jeopardizes the individual's safety.
- Coronary heart disease or other cardiovascular disorder;
- Lifetime history of heart attack;
- Cardiac rhythm disorder (irregular heart rhythm);
- Chest pains (unless history, exam, and Electrocardiogram (ECG) clearly indicate a non-cardiac source);
- Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);
- Liver or kidney disorder (except kidney stones, gallstones);
- Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;
- Active ulcers in the past 30 days;
- Lung disorder (including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, and asthma);
- Brain abnormality or other neurological disorder (including but not limited to stroke, brain tumor, and seizure disorder);
- Recent, unexplained fainting spells;
- Problems giving blood samples;
- Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%);
- Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);
- Skin disorder;
- Autoimmune disease;
- Human immunodeficiency virus (HIV) or HIV risk behavior;
- Severe allergies;
- Other major medical condition;
- Current psychiatric disease including major depressive episode, panic attack, psychosis, bipolar disorder or eating disorder;
- Pregnant or nursing mothers;
Use (within the past 30 days) of:
- Illegal drugs (or if the urine drug screen is positive),
- Experimental (investigational) drugs;
- Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);
- Opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed)
- Smokeless tobacco (chewing tobacco, snuff), cigars, pipes or e-cigarettes;
- Nicotine replacement therapy or any other smoking cessation aid.
- Alcohol abuse - The AUDIT (Alcohol Use Disorders Identification Test) questionnaire will be used to assess alcohol abuse.
- Previous history of negative experiences with "flu" vaccine or any other vaccine.
- High chronic exposure to aluminum (occupational or medical);
- Pulmonary function test results < 60% of predicted value for FEV1 and FVC;
- Body Mass Index > 38kg/m2;
- History of psychosis or bipolar disorder;
- Prior exposure to CTY002- NicQ or any other nicotine vaccine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NIC002 Vaccine in Aluminum hydroxide
4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination.
The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
|
Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
Other Names:
|
|
Placebo Comparator: Placebo Vaccine - Aluminum hydroxide
4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination.
The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
|
Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaccine-Induced Percent Change in Brain Nicotine Area Under Curve (AUC) After Single or Multiple (7) Puffs
Time Frame: measured at week 1 and week 16
|
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
|
measured at week 1 and week 16
|
|
Vaccine-Induced Percent Change in Brain Nicotine Maximum Concentration After Single or Multiple (7) Puffs
Time Frame: measured at week 1 and week 16
|
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
|
measured at week 1 and week 16
|
|
Vaccination-Induced Percent Change in T1/2 of Brain Nicotine Accumulation After Single or Multiple (7) Puffs
Time Frame: measured at week 1 and week 16
|
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
|
measured at week 1 and week 16
|
|
Vaccination-Induced Percent Change in Initial Slope of Brain Nicotine Accumulation After a Single Puff
Time Frame: measured at week 1 and week 16
|
measured at week 1 and week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alexey G Mukhin, M.D., Ph.D., Duke University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Immunologic Factors
- Gastrointestinal Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Adjuvants, Immunologic
- Antacids
- Vaccines
- Nicotine
- Aluminum Hydroxide
Other Study ID Numbers
Other Study ID Numbers
- Pro00019787
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Dependence
-
NCT03194958CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes
-
NCT03194919RecruitingNicotine Dependence, Cigarettes
-
NCT06965296Not yet recruitingNicotine Dependence, Cigarettes
-
NCT03492463Completed
-
NCT02986711TerminatedNicotine Dependence, Cigarettes
-
NCT03473483WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco Toxicity
-
NCT03276767RecruitingNicotine Dependence Tobacco Product
-
NCT04805515CompletedNicotine Dependence, Cigarettes
-
NCT04830384CompletedNicotine Dependence, Cigarettes
Clinical Trials on NIC002 in Aluminum hydroxide (Alum)
-
NCT00529399Completed
-
NCT03783130CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention
-
NCT03049488Completed
-
NCT02067676CompletedCampylobacter Infection
-
NCT01734408CompletedEV71-associated Disease
-
NCT03879603CompletedAlphavirus Infections | Eastern Equine Encephalitis | Venezuelan Equine Encephalitis | Western Equine Encephalitis
-
NCT04985760Completed
-
NCT04177355Completed